Excessive daily TV at older age tied to poorer memory

| March 1, 2019

article image
Older people who want to preserve their faculties may wish to consider rationing their TV time. A large new study of older adults found that those who spent at least 3.5 hours per day watching TV experienced a greater decline in verbal memory. Researchers at University College London in the United Kingdom analyzed data from the English Longitudinal Study of Ageing (ELSA) on 3,662 adults aged 50 and older.

Spotlight

Synergy CRO

Since 2002, SRG provides support to the pharmaceutical, biotechnology and medical device industries with a comprehensive range of collaborative services and solutions. In order to help our clients meet their clinical research goals we constantly explore and implement new ways to evolve the drug development process as well as look for cost-effective solutions. Through this work, we have come to value and respect up to date technologies along with time-tested traditional solutions. Loyalty to traditions, Openness to innovation With its unique philosophic mindset, Synergy is now the leading full-service contract research organization (CRO).

OTHER ARTICLES

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 10, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 10, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | April 10, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

How pharma can continue engaging HCPs in a world gripped by COVID-19

Article | April 10, 2020

Medscape is the leading source of clinical news, health information, and point-of-care tools for healthcare professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses and other educational programmes for physicians, nurses, and other healthcare professionals. Both Medscape and Medscape Education are part of WebMD Health Corp., an Internet Brands company. Face-to-face interactions between pharma and physicians have essentially ceased overnight during the COVID-19 pandemic, but that doesn’t mean HCPs have stopped looking for new medical information.

Read More

Spotlight

Synergy CRO

Since 2002, SRG provides support to the pharmaceutical, biotechnology and medical device industries with a comprehensive range of collaborative services and solutions. In order to help our clients meet their clinical research goals we constantly explore and implement new ways to evolve the drug development process as well as look for cost-effective solutions. Through this work, we have come to value and respect up to date technologies along with time-tested traditional solutions. Loyalty to traditions, Openness to innovation With its unique philosophic mindset, Synergy is now the leading full-service contract research organization (CRO).

Events